In recent decades, the medical toolbox has expanded dramatically. While traditional medicine relied on synthetic drugs (small molecules interacting with specific pathways) and later biologicals like antibodies, we have now entered the era of “living drugs.” These Advanced Therapy Medicinal Products (ATMPs) have the potential to fundamentally change what medicine can achieve, offering the ability to repair, replace, or reprogram biological functions at their source.
However, the journey from a ground-breaking academic concept to a clinical treatment is fraught with challenges. In the webinar we hosted on December 1st, our guest speaker, Aiko Ballardini, Quality Control Specialist from the Innovation Center for Advanced Therapies (ICAT) at UMC Utrecht, discussed how a specialized GMP Simulation unit is helping to navigate the complex path of ATMP translation.
The Challenge of Good Manufacturing Practices (GMP)
ATMPs are a heterogeneous group of products, including gene therapies, somatic cell therapies, and tissue-engineered products. Since they are intended for human use, they must be manufactured under strict Good Manufacturing Practices (GMP).
For academic researchers, GMP represents a significant hurdle. It is not merely about testing the final product; it is a comprehensive system requiring qualified premises and equipment, validated procedures, thorough risk assessments, and extensively trained personnel. In an academic setting, the lack of specific regulatory expertise and GMP knowledge often creates a gap between preclinical research and clinical application, a gap where unfortunately many promising therapies stall.
Their Solution: A GMP Simulation Facility
To bridge this gap, the ICAT established a GMP simulation facility. Located at the Utrecht Science Park, this infrastructure is designed to mimic the GMP manufacturing environment during the early development phase.
The facility allows researchers to “simulate” the production process before moving to a fully certified GMP facility. This approach involves a multidisciplinary team of quality specialists, regulatory experts, process experts and technicians who work together to ensure that the manufacturing process is robust and compliant from the start.
Key functions of the simulation unit include:
- Process and Analytical Development: Supporting the creation of robust production methods and quality control tests.
- Training: Qualifying personnel on GMP awareness, documentation, and aseptic procedures.
- Regulatory Support: Assisting with the complex documentation required for clinical trial applications, such as the Investigational Medicinal Product Dossier (IMPD).
Real-World Applications: PACMAN and TEG001
During the webinar, Aiko presented two case studies from UMC Utrecht that illustrate the importance of this infrastructure.
PACMAN (CAR T-cell Therapy)
This project involves the in-house production of CAR T-cells for cancer treatment. The GMP simulation facility played a crucial role in developing the quality control methods and preparing the regulatory dossier for the clinical trial application. Ballardini emphasized the importance of defining a “Target Product Profile”. This profile is a strategic document outlining the desired attributes of the final product and it helps guide the development decisions and ensure they align with long-term goals.
This therapy engineers αβ T cells to express a specific γδ T cell receptor. The translation of this concept from the lab to a Phase 1 clinical trial took 15 years, highlighting the extensive time required to demonstrate that a process is feasible and robust enough for GMP conditions.
Accelerating Access to Patients
The lesson from these case studies is clear: early engagement with GMP principles is essential. Researchers can identify and address potential bottlenecks by simulating GMP conditions early in development, such as raw material suitability or process scalability, before they become costly problems.
Ultimately, the goal of the GMP simulation unit is to speed up the translation of ATMPs. By integrating scientific innovation with regulatory compliance, centers like ICAT aim to overcome the obstacles of ATMP development and ensure these groundbreaking therapies reach patients more rapidly.
About the Speaker
Aiko Ballardini is a Quality Control Specialist at the Innovation Center for Advanced Therapies (ICAT), University Medical Center Utrecht (UMCU). With an academic background in Biotechnology and Biomedical Sciences, she contributes to defining and implementing quality control strategies for ATMPs. Her work focuses on bridging the gap between scientific innovation and regulatory compliance to facilitate the safe and efficient clinical translation of advanced therapies. We extend a sincere thank you to Aiko Ballardini for the great presentation and to all our partners who attended and participated in the engaging Q&A session.